Cargando…
A first-in-class POLRMT specific inhibitor IMT1 suppresses endometrial carcinoma cell growth
Exploring novel molecularly-targeted therapies for endometrial carcinoma is important. The current study explored the potential anti-endometrial carcinoma activity by a first-in-class POLRMT (RNA polymerase mitochondrial) inhibitor IMT1. In patient-derived primary human endometrial carcinoma cells a...
Autores principales: | Li, Shu-ping, Ou, Li, Zhang, Yan, Shen, Fang-rong, Chen, You-guo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950144/ https://www.ncbi.nlm.nih.gov/pubmed/36823110 http://dx.doi.org/10.1038/s41419-023-05682-7 |
Ejemplares similares
-
The mitochondrial RNA polymerase POLRMT promotes skin squamous cell carcinoma cell growth
por: Wang, Yulong, et al.
Publicado: (2022) -
POLRMT mutations impair mitochondrial transcription causing neurological disease
por: Oláhová, Monika, et al.
Publicado: (2021) -
Identification of the mitochondrial protein POLRMT as a potential therapeutic target of prostate cancer
por: Li, Xiaojun, et al.
Publicado: (2023) -
Targeting Mitochondrial Metabolism and RNA Polymerase POLRMT to Overcome Multidrug Resistance in Cancer
por: Yu, Hui-Jing, et al.
Publicado: (2021) -
Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
por: Zorzopulos, Jorge, et al.
Publicado: (2017)